VERU INC. Finance Lease, Principal Payments
VERU INC. (VERU) reported Finance Lease, Principal Payments of $9.09 thousand for the 12-month period ending 2022-09-30, per its 10-K/A filed 2024-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2024-04-01
- VERU INC. finance lease, principal payments for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. finance lease, principal payments for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. finance lease, principal payments for the quarter ending 2022-03-31 was $3.65K, a 23.28% decline year-over-year.
- VERU INC. finance lease, principal payments for the quarter ending 2021-12-31 was $5.44K, a 18.36% increase year-over-year.
- VERU INC. finance lease, principal payments for fiscal 2022 was $9.09K, a 53.21% decline from fiscal 2021.
- VERU INC. finance lease, principal payments for fiscal 2021 was $19.43K, a 41.01% increase from fiscal 2020.
- VERU INC. finance lease, principal payments for fiscal 2020 was $13.78K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $3.65K derived: sum of 3 quarters · filed 2024-04-01 | $9.09K 10-K/A · filed 2024-04-01 |
| 2022-06-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $3.65K derived: sum of 2 quarters · filed 2023-11-15 | $9.09K 10-Q/A · filed 2023-11-15 | $14.24K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-03-31 | $3.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-11 | $9.09K 10-Q · filed 2023-05-11 | $14.24K derived: sum of 3 quarters · filed 2023-05-11 | $19.17K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.44K 10-Q · filed 2023-02-09 | $10.59K derived: sum of 2 quarters · filed 2023-02-09 | $15.52K derived: sum of 3 quarters · filed 2023-02-09 | $20.28K derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $5.15K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $10.08K derived: sum of 2 quarters · filed 2022-12-05 | $14.84K derived: sum of 3 quarters · filed 2022-12-05 | $19.43K 10-K · filed 2022-12-05 |
| 2021-06-30 | $4.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $9.69K derived: sum of 2 quarters · filed 2022-08-11 | $14.28K 10-Q · filed 2022-08-11 | $18.62K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $9.36K 10-Q · filed 2022-05-12 | $13.70K derived: sum of 3 quarters · filed 2022-05-12 | $17.84K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $4.60K 10-Q · filed 2022-02-09 | $8.94K derived: sum of 2 quarters · filed 2022-02-09 | $13.08K derived: sum of 3 quarters · filed 2022-02-09 | $17.08K derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $4.34K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $8.48K derived: sum of 2 quarters · filed 2021-12-02 | $12.48K derived: sum of 3 quarters · filed 2021-12-02 | $13.78K 10-K · filed 2021-12-02 |
| 2020-06-30 | $4.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $8.14K derived: sum of 2 quarters · filed 2021-08-12 | $9.44K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | $5.30K 10-Q · filed 2021-05-12 | ||
| 2019-12-31 | $1.30K 10-Q · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |